Stage and cancer-specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population-based study
Language English Country Australia Media print-electronic
Document type Journal Article
PubMed
34480378
DOI
10.1111/iju.14682
Knihovny.cz E-resources
- Keywords
- Chinese, Epidemiology and End Results database, Surveillance, ethnicity, race, survival,
- MeSH
- Ethnicity MeSH
- Carcinoma, Transitional Cell * surgery MeSH
- Humans MeSH
- Urinary Bladder Neoplasms * MeSH
- Ureteral Neoplasms * surgery MeSH
- Retrospective Studies MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- North America epidemiology MeSH
OBJECTIVES: To examine the effect of specific Asian ethnic subgroups on stage at presentation and cancer-specific mortality in non-metastatic upper tract urothelial carcinoma among North American upper tract urothelial carcinoma Asian patients treated with radical nephroureterectomy. METHODS: We relied on the Surveillance, Epidemiology and End Results database, from 2004 to 2016. Kaplan-Meier plots and multivariable Cox regression models predicting cancer-specific mortality were used. RESULTS: Of 584 upper tract urothelial carcinoma patients, 173 (29.6%) were Chinese versus 130 (22.3%) Japanese versus 68 (11.6%) Korean versus 64 (11.0%) Filipino versus 40 (6.8%) Vietnamese versus 109 (18.7%) other. Vietnamese and Chinese patients showed the highest rates of T4 N0 M0 and/or T1-4 N1-2 M0 (25.0% and 18.5%, respectively), relative to other Asian ethnic subgroups. In Kaplan-Meier plots, Vietnamese patients showed the highest cancer-specific mortality rate. In multivariable models, Vietnamese ethnicity also independently predicted higher cancer-specific mortality (hazard ratio 2.15, P = 0.02 and hazard ratio 1.96, P = 0.03), relative to Japanese and Chinese patients. All other Asian ethnic subgroups showed similar cancer-specific mortality patterns. CONCLUSION: Vietnamese and Chinese patients are at a stage disadvantage at upper tract urothelial carcinoma diagnosis, relative to all other Asian ethnicities. After adjustment for stage, only Vietnamese patients showed a survival disadvantage relative to all other Asian ethnic subgroups. As a result, it appears that Vietnamese patients not only present at a higher upper tract urothelial carcinoma stage, but additionally appear to harbor upper tract urothelial carcinoma that progresses at a faster rate than in other Asian ethnic subgroups.
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Urology University Hospital Frankfurt Frankfurt am Main Germany
Department of Urology University of Texas Southwestern Medical Center Dallas Texas USA
Department of Urology Weill Cornell Medical College New York City New York USA
Martini Klinik Prostate Cancer Center University Hospital Hamburg Eppendorf Hamburg Germany
See more in PubMed
U.S. Census Bureau. QuickFacts: United States. [Cited 25 Mar 2020.] Available from URL: https://www.census.gov/quickfacts/fact/table/US/PST045219.
Colby SL, Ortman JM. Projections of the size and composition of the U.S. population: 2014 to 2060. 2015. [Cited 31 Aug 2021.] Available from URL: https://www.census.gov/content/dam/Census/library/publications/2015/demo/p25-1143.pdf.
Islam NS, Khan S, Kwon S, Jang D, Ro M, Trinh-Shevrin C. Methodological issues in the collection, analysis, and reporting of granular data in Asian American populations: historical challenges and potential solutions. J. Health Care Poor Underserved. 2010; 21: 1354-81.
Collà Ruvolo C, Wenzel M, Nocera L. The effect of race on stage at presentation and survival in upper tract urothelial carcinoma. Urol. Oncol. 2021; http://doi.org/10.1016/j.urolonc.2021.07.001.
U.S. Census Bureau. Asian alone or in combination with one or more other races, and with one or more asian categories for selected groups. Official website of United States Census Bureau. 2018.
Rouprêt M, Babjuk M, Burger M et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur. Urol. 2021; 79: 62-79.
Collà Ruvolo C, Nocera L, Stolzenbach LF et al. Incidence and survival rates of contemporary patients with invasive upper tract urothelial carcinoma. Eur. Urol. Oncol. 2020; https://doi.org/10.1016/j.euo.2020.11.005.
Collà Ruvolo C, Nocera L, Stolzenbach LF et al. Tumor size predicts muscle-invasive and non-organ-confined disease in upper tract urothelial carcinoma at radical nephroureterectomy. Eur. Urol. Focus 2021; https://doi.org/10.1016/j.euf.2021.03.003.
Surveillance, Epidemiology, and End Results Program. Number of persons by race and Hispanic ethnicity for SEER participants (2010 census data). [Cited 15 Mar 2020.] Available from URL: https://seer.cancer.gov/registries/data.html
Brawley OW. Some thoughts on health surveillance data, race, and population categorization: some thoughts on healthcare data, race and population categorization. CA Cancer J. Clin. 2016; 66: 179-81.
Surveillance, Epidemiology, and End Results Program. SEER incidence database. [Cited 8 Oct 2020.] Available from URL: https://seer.cancer.gov/data/index.html
Collà Ruvolo C, Würnschimmel C, Wenzel M et al. Comparison between 1973 and 2004/2016 World Health Organization grading in upper tract urothelial carcinoma treated with radical nephroureterectomy. Int. J. Clin. Oncol. 2021; 26: 1707-13.
Rink M, Fajkovic H, Cha EK et al. Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur. Urol. 2012; 61: 854-5.
Stolzenbach LF, Deuker M, Collà-Ruvolo C et al. Differences between rural and urban prostate cancer patients. World J. Urol. 2021; 39: 2507-14.
Collà Ruvolo C, Stolzenbach LF, Nocera L et al. Higher cancer mortality in rural upper urinary tract urothelial carcinoma patients. Urol. Int. 2021; 105: 624-30.
Singla N, Fang D, Su X et al. A multi-institutional comparison of clinicopathological characteristics and oncologic outcomes of upper tract urothelial carcinoma in China and the United States. J. Urol. 2017; 197: 1208-13.
Matsumoto K, Novara G, Gupta A et al. Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study: ethnic differences in upper tract urothelial carcinoma outcomes. BJU Int. 2011; 108: E304-9.
Cook LS, Goldoft M, Schwartz SM, Weiss NS. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J. Urol. 1999; 161: 152-5.
Lee J, Demissie K, Lu S-E, Rhoads GG. Cancer incidence among Korean-American immigrants in the United States and Native Koreans in South Korea. Cancer Control. 2007; 14: 78-85.
Marks LS, Kojima M, Demarzo A et al. Prostate cancer in native Japanese and Japanese-American men: effects of dietary differences on prostatic tissue. Urology 2004; 64: 765-71.
\x93\x93Rouprêt M, Babjuk M, Burger M et al. Upper urinary tract urothelial cell carcinoma. [Cited 20 Apr 2020.] Available from URL: https://uroweb.org/guideline/upper-urinary-tract-urothelial-cell-carcinoma/#note_10.
Margulis V, Puligandla M, Trabulsi EJ et al. Phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high grade upper tract urothelial carcinoma. J. Urol. 2020; 203: 690-8.
Califano G, Xylinas E. Re: phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high grade upper tract urothelial carcinoma. Eur. Urol. 2020; 78: 113-4.
Birtle A, Johnson M, Chester J et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet 2020; 395: 1268-77.
Califano G, Ouzaid I, Verze P, Hermieu J-F, Mirone V, Xylinas E. Immune checkpoint inhibition in upper tract urothelial carcinoma. World J. Urol. 2021; 39: 1357-67.
